These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 25376133

  • 1. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas.
    Kurosaki M, Kambe A, Watanabe T, Fujii S, Ogawa T.
    Neurol Res; 2015 Apr; 37(4):341-6. PubMed ID: 25376133
    [Abstract] [Full Text] [Related]

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 3. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 4. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G.
    N Engl J Med; 2003 Nov 20; 349(21):2023-33. PubMed ID: 14627787
    [Abstract] [Full Text] [Related]

  • 5. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
    Clin Endocrinol (Oxf); 2003 May 20; 58(5):662-70. PubMed ID: 12699451
    [Abstract] [Full Text] [Related]

  • 6. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr 20; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 7. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL.
    Pituitary; 2007 Apr 20; 10(3):261-6. PubMed ID: 17557207
    [Abstract] [Full Text] [Related]

  • 8. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L.
    Acta Eur Fertil; 1995 Apr 20; 26(3):105-7. PubMed ID: 9098469
    [Abstract] [Full Text] [Related]

  • 9. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T.
    J Clin Endocrinol Metab; 2010 Jun 20; 95(6):2672-9. PubMed ID: 20357175
    [Abstract] [Full Text] [Related]

  • 10. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.
    Pol Arch Med Wewn; 2003 May 20; 109(5):489-95. PubMed ID: 14768178
    [Abstract] [Full Text] [Related]

  • 11. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 20; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 12. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
    Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T.
    Pituitary; 2000 May 20; 2(4):277-81. PubMed ID: 11081149
    [Abstract] [Full Text] [Related]

  • 13. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E, Kaźmierczyk-Puchalska A, Zochowska E, Sowińska-Przepiera E, Sagan L, Kojder I, Syrenicz A.
    Pomeranian J Life Sci; 2015 May 20; 61(3):263-9. PubMed ID: 27344867
    [Abstract] [Full Text] [Related]

  • 14. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF.
    Clin Endocrinol (Oxf); 1997 Apr 20; 46(4):409-13. PubMed ID: 9196602
    [Abstract] [Full Text] [Related]

  • 15. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F.
    J Endocrinol Invest; 1999 May 20; 22(5):354-9. PubMed ID: 10401709
    [Abstract] [Full Text] [Related]

  • 16. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G.
    Pituitary; 2002 May 20; 5(4):261-5. PubMed ID: 14558675
    [Abstract] [Full Text] [Related]

  • 17. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A, Benbassat C, Shimon I.
    Endocr Pract; 2015 Nov 20; 21(11):1240-7. PubMed ID: 26247115
    [Abstract] [Full Text] [Related]

  • 18. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
    Cannavò S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F.
    J Endocrinol Invest; 1999 Apr 20; 22(4):306-9. PubMed ID: 10342366
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.
    Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S.
    Indian J Med Res; 2010 Apr 20; 131():530-5. PubMed ID: 20424304
    [Abstract] [Full Text] [Related]

  • 20. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y, Ueno Y, Horikawa F, Miyake H, Miki N, Ono M.
    Surg Neurol; 2008 Jan 20; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.